Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Roche's Sefaxersen sodium?
Sefaxersen sodium is an antisense oligonucleotide commercialized by Roche, with a leading Phase III program in IgA Nephropathy (Berger's Disease)....
Data Insights
Sefaxersen sodium by F. Hoffmann-La Roche for Geographic Atrophy: Likelihood of Approval
Sefaxersen sodium is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Geographic Atrophy. According to...